In 2017, avelumab (anti–programmed death-ligand 1 (PD-L1))became the first approved treatment for patients with metastatic MCC (mMCC), based onthe occurrence of durable responses in a subset of patients. The gene discussed is CD274; the disease is Merkel cell skin cancer.